Shares of Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.47 and traded as low as $0.3450. Elite Pharmaceuticals shares last traded at $0.3460, with a volume of 394,100 shares changing hands.
Elite Pharmaceuticals Stock Performance
The company's fifty day moving average price is $0.38 and its 200 day moving average price is $0.47. The company has a market cap of $372.69 million, a PE ratio of 11.54 and a beta of 0.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 7.34 and a quick ratio of 5.44.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last announced its earnings results on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 EPS for the quarter. The company had revenue of $31.59 million during the quarter. Elite Pharmaceuticals had a net margin of 30.98% and a return on equity of 47.93%.
About Elite Pharmaceuticals
(
Get Free Report)
Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.
Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
